α-MSH对博莱霉素诱导小鼠肺纤维化中抗纤维化作用的初步研究

doi:10.3969/j.issn.1001-8131.2025.06.001

Abstract
Figure/Table
References (0)
Related Citation (6)

Download: PDF (842 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of α-MSH on the fibrosis factor type I collagen,key nuclear factor in TNF-α and immune-regulation pathway,we initially investigated whether α-MSH has an anti-fibrotic effect in different periods of pulmonary fibrosis. Methods The mouse lung fibrosis model was constructed by bleomycin tracheal drip method,and α-MSH was treated in the first,second and third weeks of animal model to detect the expression of type I collagen,TNF-α mRNA and production of NF-κB protein,and the generation of TNF-α in peripheral blood and alveolar lavage fluid. Results α-MSH could significantly inhibit the expression of type I collagen and TNF-α gene.The production of p-NF-κB protein in the mouse model of bleomycin-induced pulmonary fibrosis could inhibit by α-MSH,which had obvious anti-inflammatory and anti-fibrosis effect.Furthermore α-MSH began to exert this effect in the early stage of the fibrosis,and had the characteristics of long maintenance time.It suggests that α-MSH has an important role in the early immune action mechanism of pulmonary fibrosis. Conclusion α-MSH may be a new target for early treatment of IPF and has great value for early prevention and treatment of IPF.

Key words： Idiopathic pulmonary fibrosis Alpha-melanocyte-stimulating hormone type I collagen tumor necrosis factor

Received: 26 May 2025

PACS:

R563.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Xiao Rui
	Zhang Weimin
	Mai Huiru
	Zhou Jintian
	Xu Chunguang

Cite this article:

Xiao Rui,Zhang Weimin,Mai Huiru, et al. Anti Fibrosis Effect of α-MSH on Bleomycin Induced Pulmonary Fibrosis in Mice[J]. journal1, 2025, 45(6): 1-4.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2025.06.001 OR http://www.hrbyybjb.org.cn/EN/Y2025/V45/I6/1

[1] Koudstaal T,Funke-Chambour M,Kreuter M,et al.Pulmonary fibrosis:from pathogenesis to clinical decision-making[J].Trends Mol Med,2023,29(12):1076-1087.
[2] Dickson RP,Erb-Downward JR,Martinez FJ,et al.The Mi-crobiome and the Respiratory Tract[J].Annu Rev Physiol,2016,78:481-504.
[3] Li Y,Jiang C,Zhu W,et al.Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis.Sci Prog[J].2024,107(2):368-379.
[4] Selvarajah B,Platé M,Chambers RC.Pulmonary fibrosis:Emerging diagnostic and therapeutic strategies[J].Mol Aspects Med.2023,94:101-127.
[5] Savin IA,Zenkova MA,Sen'kova AV.Pulmonary Fibrosis as a Result of Acute Lung Inflammation:Molecular Mechanisms,Relevant In Vivo Models,Prognostic and Therapeutic Approaches[J].Int J Mol Sci.2022,23(23):232-254.
[6] Heukels P,Moor CC,von der Thüsen JH,et al.Inflammation and immunity in IPF pathogenesis and treatment[J].Respir Med.2019,147(2):79-91.
[7] Weng WT,Wu CS,Wang FS,et al.α-Melanocyte-Stim-ulating Hormone Attenuates Neovascularization by Inducing Nitric Oxide Deficiency via MC-Rs/PKA/NF-κB Sig-naling[J].Int J Mol Sci.2018,19(12):38-43.
[8] Webering S,Lunding LP,Vock C,et al.The alpha-me-lanocyte-stimulating hormone acts as a local immune homeostasis factor in experimental allergic asthma[J].Clin Exp Allergy.2019,49(7):1026-1039.
[9] Colombo G,Gatti S,Sordi A,et al.Production and effects of alpha-melanocyte-stimulating hormone during acute lung injury[J].Shock.2007,27(3):326-333.
[10] Dinparastisaleh R,Mirsaeidi M.Antifibrotic and Anti-In-flammatory Actions of α-Melanocytic Hormone:New Roles for an Old Player.Pharmaceuticals(Basel)[J].2021,14(1):45-55.
[11] O’Dwyer DN,Armstrong ME,Trujillo G,et al.The Toll-like receptor 3 L412F polymorphism and disease pro-gression in idiopathic pulmonary fibrosis[J].Am J Respir Crit Care Med.2013,188:1442-1450.
[12] Xu PB,Mao YF,Meng HB,et al.STY39,a novel alpha-melanocyte-stimulating hormone analogue,attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice[J].Shock.2011,35(3):308-314.
[13] Olson AL,Swigris JJ,Lezotte DC,et al.Mortality from pulmonary fifibrosis increased in the United States from 1992 to 2003[J].Am J Respir Crit Care Med 2007,176:277-284.
[14] Mirsaeidi M,Machado RF,Schraufnagel D,et al.Racial difference in sarcoidosis mortality in the United States[J].Chest.2015,147:438-439.